A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: Increased neuroprotective efficacy and extended therapeutic time window

Journal of Cerebral Blood Flow and Metabolism

Volumn 22, Issue 10, 2002, Pages 1205-1211

  Maeda, Masashi ^a   Furuichi, Yasuhisa ^a   Ueyama, Noriko ^a   Moriguchi, Akira ^a   Satoh, Natsuki ^a   Matsuoka, Nobuya ^a   Goto, Toshio ^a   Yanagihara, Takehiko ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cerebral ischemia; Combination therapy; FK506; Middle cerebral artery; Neuroprotection; Rat; Recombinant tissue plasminogen activator

Indexed keywords

ALTEPLASE; ROSE BENGAL; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; GREEN LIGHT; LIGHT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PHOTOCHEMISTRY; PRIORITY JOURNAL; RAT;

EID: 0036791876     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wcb.0000037993.34930.72     Document Type: Article

References (27)

1. Andersen M, Overgaard K, Meden P, Boysen G (1999) Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke 30:1464-1471
2. Asahi M, Asahi K, Wang X, Lo EH (2000) Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 20:452-457
3. Chen ZL, Strickland S (1997) Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 91:917-925
4. Clark WM, Madden KP, Lyden PD, Zivin JA (1991) Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke 22:872-876
5. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, Hennerici M (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 274:1017-1025
6. Hankey GJ, Warlow CP (1999) Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 354:1457-1463
7. Hossmann KA (1994) Viability thresholds and the penumbra of focal ischemia. Ann Neurol 36:557-565
8. Kaste M (2001) Thrombolysis in ischemic stroke-present and future: role of combined therapy. Cerebrovasc Dis 11(Suppl 1):55-59
9. Kawai H, Umemura K, Nakashima M (1995) Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn J Pharmacol 69:143-148
10. Lekieffre D, Benavides J, Scatton B, Nowicki J-P (1997) Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model. Brain Res 776:88-95
11. Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Asai Y, Muranaka Y, Nakashima M (1993) A simple and reproducible cerebral thrombosis model in rats induced by a photochemical reaction and the effect of a plasminogen-plasminogen activator chimera in this model. J Pharmacol Toxicol Methods 29:165-173
12. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute hemispheric stroke. N Engl J Med 333:1581-1587
13. Overgaard K, Sereghy T, Pedersen H, Boysen G (1992) Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. Neuroreport 3:925-928
14. Rosen GD, Harry JD (1990) Brain volume estimation from serial section measurements: a comparison of methodologies. J Neurosci Methods 35:115-124
15. Sereghy T, Overgaard K, Boysen G (1993) Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 24:1702-1708
16. Sharkey J, Butcher SP (1994) Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischemia. Nature 371:336-339
17. Sharkey J, Crawford JH, Butcher SP, Marston HM (1996) Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. Stroke 27:2282-2286
18. Sharkey J, Jones PA, McCarter JF, Kelly JS (2000) Calcineurin inhibitors as neuroprotectants: focus of tacrolimus and cyclosporin. CNS Drugs 13:1-13
19. Takamatsu H, Kondo K, Ikeda Y, Umemura K (1998) Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion. Eur J Pharmacol 362:137-142
20. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamaoto K, Kiryu J, Honda Y (1998) Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia. Stroke 29:1431-1438
21. Umemura K, Wada K, Uematsu T, Nakashima M (1993) Evaluation of the combination of tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 24:1077-1082
22. Wakabayashi H, Karasawa Y, Tanaka S, Kokudo Y, Maeba T (1994) The effect of FK506 on warm ischemia and reperfusion injury in the rat liver. Surg Today 24:994-1002
23. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPAdeficient mice. Nature Med 4:228-231
24. Warlow CP (1998) Epidemiology of stroke. Lancet 352:1-4
25. Yagita Y, Kitagawa K, Matsushita K, Taguchi A, Mabuchi T, Ohtsuki T, Yanagihara T, Matsumoto M (1996) Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. Life Sci 59:1643-1650
26. Zhang RL, Zhang ZG, Chopp M (1999) Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 30:624-629
27. Zivin JA, Mazzarella V (1991) Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 48:1235-1238